Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) COO Ganesh Venkataraman Kaundinya sold 1,917 shares of the company’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $16.00, for a total value of $30,672.00. Following the sale, the chief operating officer now owns 492,845 shares of the company’s stock, valued at approximately $7,885,520. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Ganesh Venkataraman Kaundinya also recently made the following trade(s):
- On Tuesday, November 21st, Ganesh Venkataraman Kaundinya sold 821 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $13.15, for a total value of $10,796.15.
Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) traded up $0.05 during midday trading on Monday, hitting $16.30. The company had a trading volume of 571,269 shares, compared to its average volume of 921,225. Momenta Pharmaceuticals, Inc. has a fifty-two week low of $11.85 and a fifty-two week high of $19.46. The firm has a market cap of $1,250.00, a PE ratio of -20.38 and a beta of 1.80.
MNTA has been the subject of several recent analyst reports. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Cowen set a $15.00 price target on Momenta Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 1st. BidaskClub downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $18.00 price target on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating and ten have assigned a hold rating to the company. The stock has an average rating of “Hold” and a consensus price target of $15.30.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.